Key facts
- It has raised $5.4M; the latest was Seed Round ($1.2M) in Apr 2025.
- Notable investors include Lux Capital, S32.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Biosynch
- ·The full record, as it builds
Funding rounds
No funding rounds for Biosynch are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biosynch
Developer of bioinformatics and computational biology systems designed to support biological data analysis and research applications in life sciences. The company's platform integrates machine learning models, biological data processing pipelines and computational analysis tools capable of handling genomic and molecular datasets, supporting tasks such as biomarker discovery, biological pattern recognition, predictive modeling and interpretation of complex biological information, enabling researchers, biotechnology companies and healthcare organizations to analyze biological data and generate research insights for applications in precision medicine, drug discovery and disease research.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Employees
- 56
- Website
- biosynchai.com/
- Ownership
- Privately Held (backing)
Biosynch doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biosynch shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biosynch in its N-PORT filings yet. We sweep new filings monthly.